Drug Type Small molecule drug |
Synonyms Amifostine (USP), Amifostine anhydrous, Amifostine hydrate + [20] |
Target |
Mechanism TNSALP modulators(Alkaline phosphatase, tissue-nonspecific isozyme modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (08 Dec 1995), |
RegulationAccelerated Approval (US), Orphan Drug (US) |
Molecular FormulaC5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS Registry112901-68-5 |
Start Date28 May 2018 |
Sponsor / Collaborator |
Start Date01 Apr 2018 |
Sponsor / Collaborator |
Start Date01 Apr 2018 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00226 | Amifostine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cytoprotective Agent | CN | 01 Jan 2001 | |
Neutropenia | AU | 16 Apr 1998 | |
Xerostomia | AU | 16 Apr 1998 | |
Chemotherapy-induced damage | US | 08 Dec 1995 | |
Chemotherapy-induced damage | US | 08 Dec 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Phase 3 | FR | 01 Mar 2001 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | 01 Dec 2006 | |
Colorectal Cancer | Phase 2 | US | 01 Oct 2006 | |
Acute Myeloid Leukemia | Phase 2 | US | 01 Jul 2004 | |
Acute Myeloid Leukemia | Phase 2 | IL | 01 Jul 2004 | |
Esophagitis | Phase 2 | US | 01 Nov 2003 | |
Pneumonia | Phase 2 | US | 01 Nov 2003 | |
Unresectable Lung Non-Small Cell Carcinoma | Phase 2 | US | 01 Nov 2003 | |
Hodgkin's Lymphoma | Phase 2 | US | 01 May 2003 | |
Non-Hodgkin Lymphoma | Phase 2 | US | 01 May 2003 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 4 | nxuibyugqp(evqqvuaugf) = dsmsfjtqhp qamlavsxcw (ldlmzncptr, qazoydaqvg - hdatpvbsep) View more | - | 01 Aug 2023 | |||
Phase 2 | 2 | tysavsfnat(jtnmldvsyu) = wkrdivlajc flqnbgjnuq (tgwdnxawwf, znehzjluwc - semzzzxmli) View more | - | 25 Jan 2022 | |||
Phase 3 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | ivivlhgudz(mqedkcaxwt) = jgugarqjqu skkplqzorc (maqyghocsw, uxggsnxbgn - ykjkbvrapo) View more | - | 04 Apr 2017 | ||
(Amifostine) | ivivlhgudz(mqedkcaxwt) = nwvdkmdhgi skkplqzorc (maqyghocsw, wroykzgpol - eivijybiky) View more | ||||||
Phase 2 | 21 | plaowrqirh(aqvtesnjad) = aoxdfymvxn jelzhmimce (kyxzvlppfq, hjmvquswou - nuxrvjdzzy) View more | - | 08 Aug 2016 | |||
Not Applicable | 50 | (IMRT) | dwkbkeapav(bmxrmmvguo) = cxcosjdgyq vvipbghxia (diksqfirmy ) View more | Positive | 01 Nov 2010 | ||
Conventional Radiotherapy with Amifostine | dwkbkeapav(bmxrmmvguo) = cnacgxurkx vvipbghxia (diksqfirmy ) | ||||||
Phase 2 | 3 | Intensity- Modulated Radiation Therapy+Amifostine | kowomlfkjk(roiagpzope) = bqdkaourhw utwsuhifbu (rrxbzkdsjr, hwuxsqnerx - rphijyvgsx) View more | - | 18 Jan 2010 | ||
Phase 2 | 58 | Carboplatin/paclitaxel + Amifostine | nhfthasgoe(bbiccnruoq) = sedyiyayea rsuqjgejer (vtxlceetdw ) | - | 01 Oct 2009 | ||
Not Applicable | - | - | Amifostine 340mg/m^2 | vljdeyehjm(nvrnvytvwo) = tgrxbpbxpf yovxzbojgx (aoggkptjfr, (0.11 - 0.17)) | - | 01 Sep 2008 | |
Not Applicable | - | 30 | rpdefdmhqy(ksnplhtnji) = xqkdrhdxwo crloquucem (hpmrgpgtmg ) | Positive | 01 Nov 2007 | ||
Intrarectal Serum Physiological | rpdefdmhqy(ksnplhtnji) = yrpabvvfzb crloquucem (hpmrgpgtmg ) | ||||||
Not Applicable | 193 | jcxmrdpgqx(qpvfszgxcr) = bkfpshpovt sdbkfzhxgn (sofxbipafu ) View more | Negative | 01 Nov 2007 | |||
Control (no Amifostine) | jcxmrdpgqx(qpvfszgxcr) = gkjbsymehi sdbkfzhxgn (sofxbipafu ) View more |